{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:06Z","timestamp":1791849366888,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,25]]},"DOI":"10.7759\/cureus.58999","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:23:06Z","timestamp":1714058586000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib\/Cyclophosphamide\/Dexamethasone and Bortezomib\/Lenalidomide\/Dexamethasone as Upfront Treatment"],"prefix":"10.7759","author":[{"given":"Nabiha","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurrya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah","family":"Jehanzeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman N","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varisha","family":"Madni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umm E","family":"Abiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002%2Fajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk-stratification and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk-stratification and management. Am J Hematol. 2022, 97:1086-107. 10.1002%2Fajh.26590","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren O","year":"2009","unstructured":"Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009, 23:1691-7. 10.1038\/leu.2009.134","journal-title":"Leukemia"},{"key":"ref3","article-title":"Multiple myeloma","author":"Albagoush SA","year":"2023","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple myeloma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren O","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, et al.. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009, 113:5412-7. 10.1182\/blood-2008-12-194241","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle RA","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018, 378:241-9. 10.1056\/NEJMoa1709974","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar SV","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015, 125:3069-75. 10.1182\/blood-2014-09-568899","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003, 78:21-33. 10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo M","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, et al.. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010, 376:2075-85. 10.1016\/S0140-6736(10)61424-9","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson PG","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, et al.. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010, 116:679-86. 10.1182\/blood-2010-02-268862","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, et al.. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019, 393:253-64. 10.1016\/S0140-6736(18)33003-4","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016, 17:e328-46. 10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13280","article-title":"Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma","volume":"103","author":"Uttervall K","year":"2019","unstructured":"Uttervall K, Borg Bruchfeld J, Gran C, et al.. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. Eur J Haematol. 2019, 103:247-54. 10.1111\/ejh.13280","journal-title":"Eur J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.020","article-title":"Impact of induction with VCD versus VRD on the outcome of patients with multiple myeloma after an autologous hematopoietic stem cell transplantation","volume":"28","author":"Afrough A","year":"2022","unstructured":"Afrough A, Pasvolsky O, Ma J, et al.. Impact of induction with VCD versus VRD on the outcome of patients with multiple myeloma after an autologous hematopoietic stem cell transplantation. Transplant Cell Ther. 2022, 28:307.e1-8. 10.1016\/j.jtct.2022.03.020","journal-title":"Transplant Cell Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2021.100252","article-title":"Lebanese real-world experience in treating multiple myeloma: a multicenter retrospective study","volume":"15","author":"Nasr F","year":"2021","unstructured":"Nasr F, Ghoche AA, Diab S, et al.. Lebanese real-world experience in treating multiple myeloma: a multicenter retrospective study. Leuk Res Rep. 2021, 15:100252. 10.1016\/j.lrr.2021.100252","journal-title":"Leuk Res Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00879-0","article-title":"Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients","volume":"23","author":"Zhou Q","year":"2023","unstructured":"Zhou Q, Xu F, Wen J, Yue J, Zhang Y, Su J, Liu Y. Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients. Clin Exp Med. 2023, 23:1573-80. 10.1007\/s10238-022-00879-0","journal-title":"Clin Exp Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2020.05.527","article-title":"Bortezomib-based triplet regimens for remission induction in multiple myeloma","volume":"30","author":"Toor SH","year":"2020","unstructured":"Toor SH, Satti TM, Iftikhar R, Mahmood SK, Shamshad GU, Rehman JU. Bortezomib-based triplet regimens for remission induction in multiple myeloma. J Coll Physicians Surg Pak. 2020, 30:527-31. 10.29271\/jcpsp.2020.05.527","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref17","article-title":"Government of Pakistan Ministry of National Health Services, Regulations and Coordination Drug Regulatory Authority of Pakistan) S.R.O. 1092(l)2023.","year":"2023","unstructured":"Notification S.R.O. 1092(l)2023. Ministry of National Health Services, Regulations and Coordination Drug Regulatory Authority of Pakistan, Islamabad, Pakistan; 2023. https.\/\/www.dra.gov.pk\/wp-content\/uploads\/2023\/08\/SRO-1092I2023-dated-22Aug2023.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238516-real-world-outcomes-in-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma-treated-with-bortezomibcyclophosphamidedexamethasone-and-bortezomiblenalidomidedexamethasone-as-upfront-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:23:09Z","timestamp":1714058589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238516-real-world-outcomes-in-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma-treated-with-bortezomibcyclophosphamidedexamethasone-and-bortezomiblenalidomidedexamethasone-as-upfront-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.58999","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}